
Journey Medical Corporation (NASDAQ:DERM – Free Report) – Stock analysts at HC Wainwright boosted their FY2026 earnings estimates for shares of Journey Medical in a research note issued on Friday, November 13th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.26) per share for the year, up from their prior forecast of ($0.29). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Journey Medical’s current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Journey Medical’s FY2028 earnings at $0.31 EPS, FY2029 earnings at $0.47 EPS and FY2030 earnings at $0.51 EPS.
Journey Medical (NASDAQ:DERM – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The firm had revenue of $18.97 million for the quarter, compared to the consensus estimate of $20.32 million. Journey Medical had a negative net margin of 7.34% and a negative return on equity of 16.07%.
Check Out Our Latest Report on Journey Medical
Journey Medical Trading Down 5.4%
Shares of DERM stock opened at $3.69 on Tuesday. Journey Medical has a 1-year low of $3.40 and a 1-year high of $9.56. The stock’s 50-day moving average is $5.65 and its 200 day moving average is $6.40. The company has a quick ratio of 1.34, a current ratio of 1.48 and a debt-to-equity ratio of 0.56.
Hedge Funds Weigh In On Journey Medical
A number of large investors have recently made changes to their positions in DERM. Royal Bank of Canada lifted its holdings in shares of Journey Medical by 42.7% during the 1st quarter. Royal Bank of Canada now owns 8,175 shares of the company’s stock valued at $38,000 after purchasing an additional 2,446 shares during the last quarter. Cetera Investment Advisers purchased a new position in Journey Medical during the 1st quarter worth $48,000. Allegiance Financial Group Advisory Services LLC purchased a new position in Journey Medical during the 3rd quarter worth $68,000. Persistent Asset Partners Ltd purchased a new position in Journey Medical during the 2nd quarter worth $71,000. Finally, Jump Financial LLC acquired a new position in Journey Medical during the 3rd quarter valued at about $81,000. 7.25% of the stock is owned by institutional investors and hedge funds.
Journey Medical Company Profile
Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.
Featured Articles
- Five stocks we like better than Journey Medical
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with MarketBeat.com's FREE daily email newsletter.
